PT-141 long term side effects: what the trial data shows

Last updated 2026-07-25

What counts as a 'long term' side effect for PT-141?

There isn't a formal definition, but for a drug reviewed by the FDA on trial data running months rather than years, it's fair to split the question into three buckets: what happens with one dose, what happens over several months of regular use, and what happens beyond a year. Only the first two have real evidence behind them. The FDA approved bremelanotide (brand name Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women based on two randomized phase 3 trials, RECONNECT, each running 24 weeks ^[1]. A subset of participants continued into an open-label extension for up to 52 weeks total, which is the longest structured safety window that exists in the published record ^[2]. There is no published data on daily or near-daily use over multiple years, because the drug was never studied or approved that way. It's dosed as needed, not continuously. So when someone asks about "long term side effects," the honest answer splits in two: here's what a year of intermittent use looks like in trial data, and here's what we simply don't know past that.

What were the most common side effects in the phase 3 trials?

Nausea and flushing were the two side effects that showed up far more than anything else. In the RECONNECT trials, nausea was reported in a large share of bremelanotide users, roughly in the range of 40%, and flushing was also common, with headache and injection site reactions reported less frequently ^[3]. These weren't rare footnotes. They were common enough that the FDA labeling and multiple independent reviews flag them as the defining tolerability issue with this drug ^[1]. A pooled safety analysis across the clinical development program (multiple trials, more than the two main studies) confirmed the same pattern: nausea, flushing, and headache dominate the adverse event list, with nausea often decreasing in intensity with repeat dosing for many patients but not disappearing entirely for everyone ^[4]. Injection site reactions, including pain, redness, or bruising, were also reported, which makes sense given bremelanotide is given as a subcutaneous injection rather than a pill ^[1]. A meaningful minority of patients stopped taking the drug because of these effects. Discontinuation due to adverse events, largely nausea, was reported in the trials at rates that outpaced placebo discontinuation, which is a reasonable proxy for how much these side effects bothered people in real use, more than in a symptom checklist ^[3]. Hyperpigmentation, meaning focal darkening of the skin (sometimes on the face, gums, or breasts), was also reported in a smaller number of patients across the clinical program, and the FDA labeling notes this may not fully reverse after stopping the drug. This is one of the more unusual long-term concerns tied to bremelanotide's mechanism, since it activates melanocortin receptors that also drive pigmentation, more than desire pathways ^[4].

Does PT-141 raise blood pressure long term?

Yes, transiently, and this is one of the more clinically important things to understand before starting. Bremelanotide causes a temporary rise in blood pressure after each dose, along with a modest decrease in heart rate in some patients, an effect the FDA specifically warns about for people with uncontrolled hypertension or known cardiovascular disease ^[4]. This isn't a sustained, cumulative rise that gets worse dose after dose the way some might assume from the phrase "long term." It's a transient spike tied to each administration that then resolves. But because the drug is meant to be used repeatedly over months or years in real practice, that means repeated transient spikes, and nobody has long-term cardiovascular outcome data (heart attack or stroke rates over years, for instance) because the trials weren't designed or powered to catch that . A clinical review focused specifically on hypertension and female sexual dysfunction concluded that blood pressure monitoring matters more for bremelanotide candidates with existing cardiovascular risk factors than for a healthy population without them . The practical takeaway: if you have uncontrolled high blood pressure or cardiovascular disease, this is a conversation to have with a prescriber before starting, not after.

How is PT-141 different from Viagra style drugs, and why does that matter for side effects?

This is the single most useful thing to understand about bremelanotide, and it explains why its side effect profile looks so different from sildenafil or similar drugs. PT-141 doesn't work on blood vessels. It works in the brain. Sildenafil and its relatives are PDE5 inhibitors: they act locally on vascular smooth muscle to increase blood flow to genital tissue. Bremelanotide is a melanocortin receptor agonist, meaning it binds to MC4R (and related receptors) in the central nervous system, the same receptor family involved in appetite regulation and energy balance ^[5] . A CNS Spectrums review describing bremelanotide's neurobiology explains that its effect on desire is thought to work upstream of genital blood flow entirely, acting on dopaminergic pathways tied to sexual motivation in the brain rather than on vascular tissue . This matters for two reasons. First, it's why bremelanotide is approved specifically for low desire (HSDD) rather than for arousal or erectile problems, which are more mechanically, vascularly driven. Second, it's why its side effects look the way they do: nausea and flushing are classic effects of activating melanocortin pathways broadly (the same receptor family is being explored for appetite and metabolic disorders for exactly this systemic reach ^[6]), rather than a localized vascular event like the flushing seen with PDE5 inhibitors. You're not getting a local blood flow effect with off-target vascular symptoms. You're getting a brain-level signal with body-wide melanocortin activation, and nausea is the most common downstream cost of that.

Are there metabolic or weight related long term effects?

This is a genuinely interesting and under-discussed angle. Because bremelanotide acts on melanocortin receptors that also regulate appetite, researchers have specifically looked at whether it affects body weight over time. Two phase 1 randomized controlled trials in obese women examined bremelanotide's effect on body weight directly, since the melanocortin system is a known target in obesity research . The melanocortin system broadly is being studied for metabolic disorders including obesity, and MC4R agonism specifically is tied to appetite suppression in other contexts ^[5]. This doesn't mean bremelanotide is an effective or approved weight loss drug, it absolutely is not approved for that use, but it does mean the systemic reach of this receptor family is real, and appetite or weight changes are a plausible, mechanistically grounded thing to ask a prescriber about if you notice them over months of use. Nobody has published data confirming a clinically meaningful weight change in the approved HSDD population using the approved dosing schedule, so this remains a mechanistic curiosity rather than an established side effect to expect.

What does a year of use actually look like in the data?

The open-label extension of the RECONNECT program followed participants for up to 52 weeks, giving the best available picture of what sustained, as-needed use looks like over roughly a year ^[2]. The pattern that emerges: nausea remains the dominant complaint, tends to be worse with early doses and often eases somewhat with continued use, and a meaningful subset of users still stop the drug because of it or because of skin pigmentation changes. A safety profile analysis across the full clinical development program (more than RECONNECT) reinforced that no new, unexpected safety signal emerged with continued use over the studied period, but also explicitly notes the analysis is bounded by the trial duration itself, not by real-world years-long use ^[4]. That's an important distinction. "No new signal in the trial" is not the same claim as "safe indefinitely." An independent re-analysis published in the Journal of Sex Research went further, raising concerns about how the phase 3 trial data was analyzed and interpreted, arguing that the clinical significance of the desire score improvements was modest relative to the side effect burden reported . A separate critique in the same journal, titled bluntly "Small Effects, Questionable Outcomes," made a similar argument about the benefit-to-side-effect ratio in the main trials . These aren't fringe positions dismissing the drug outright, they're peer-reviewed pushback on how meaningful the trial results are once you weigh them against how often nausea and flushing showed up. A regulatory commentary comparing bremelanotide to flibanserin (Addyi) made a related point: that approval based on modest average effect sizes doesn't guarantee the drug will feel worth the side effects for any individual patient ^[7].

What about cancer, tumor growth, or other unexpected long term risks?

One line of research worth flagging honestly, without overstating it: a 2024 laboratory study found that bremelanotide, acting through melanocortin receptors, induced cell death and growth inhibition in glioblastoma (brain tumor) cells in vitro, by suppressing a protein called survivin . This is not a safety warning. It's early-stage cell culture research exploring whether melanocortin receptor agonists might have anti-tumor applications, the opposite direction of concern. It says nothing about cancer risk in people using bremelanotide for HSDD. It's mentioned here only because it shows up in searches and deserves an honest, unembellished explanation rather than silence or alarm. More broadly, melanocortin receptors are involved in inflammatory signaling, and research on melanocortin receptor gene variants has linked certain polymorphisms to inflammatory disease traits . This is basic receptor biology research, not a finding specific to bremelanotide use, and it doesn't translate into a known clinical risk for people taking Vyleesi. It's a reminder that the melanocortin system touches more of the body than desire alone, which is consistent with the systemic side effect pattern (nausea, flushing, pigmentation) already seen in the trials.

Who shouldn't use PT-141 long term, or at all?

The FDA label and multiple clinical reviews are consistent on a few groups. People with uncontrolled hypertension or known cardiovascular disease need a real conversation with a prescriber first, given the transient blood pressure and heart rate effects on each dose ^[4] . Bremelanotide is approved specifically for premenopausal women with acquired, generalized HSDD, meaning low desire that developed and isn't better explained by another medical, relationship, or psychiatric issue ^[1]. It is not approved for postmenopausal women, for men, or for arousal or orgasm disorders specifically. A Journal of Midwifery & Women's Health review on HSDD emphasizes that diagnosis itself requires ruling out other causes of low desire first (relationship issues, depression, other medications, hormonal factors), because bremelanotide won't fix low desire that has a different root cause ^[8]. That's a safety issue as much as an efficacy one: taking a melanocortin agonist for months when the actual driver is untreated depression or a relationship problem means absorbing the side effect burden for no real benefit. Anyone considering repeat, long-term as-needed use should also understand dosing limits explicitly built into the label: no more than one dose in 24 hours, no more than eight doses per month. Going outside that isn't studied and isn't safer for being unstudied, it's simply unknown. For the mechanics of that schedule, see PT-141 dosage and PT-141 cycle length.

How does PT-141's side effect profile compare across major reviews?

What don't we know yet about PT-141's long term safety?

It's worth being direct about the gaps rather than papering over them. There is no published multi-year safety surveillance data for bremelanotide. The FDA approval and the bulk of the peer-reviewed literature rest on trials lasting up to a year, with the main efficacy data drawn from 24-week trials ^{[1] [2]}. A commentary in Drug and Therapeutics Bulletin specifically questioned whether the regulatory bar for approving desire drugs like bremelanotide and flibanserin has been set appropriately given the modest and short-duration evidence base behind them ^[7]. We also don't have good data on what happens with bremelanotide sourced or dosed outside the approved, FDA-reviewed product and schedule. Compounded or research-grade versions of bremelanotide exist, but bremelanotide is not on the FDA's 503A or 503B bulks lists for compounding [and does not have to be, since it's an FDA-approved drug rather than a bulk substance nominated for compounding into new formulations]. The only version with actual human trial safety data behind it is the FDA-approved Vyleesi product, dosed exactly as studied. Straying from that (different doses, different frequency, unverified sourcing) means straying from the only evidence that exists. For readers who want the mechanistic background behind how this drug is built and why it behaves this way, see PT-141 peptide.

How should someone weigh the benefit against these side effects?

The two main phase 3 trials found a statistically significant improvement in desire and reduction in distress related to low desire compared to placebo, which is what supported FDA approval ^{[1] [9]}. But the size of that improvement, weighed against roughly 40% of patients experiencing nausea, is genuinely debated in the peer-reviewed literature, more than by critics online. The Journal of Sex Research pieces cited above made exactly this argument using the trial's own data . What this means practically: this isn't a drug where the honest answer is "the benefits clearly outweigh the risks for everyone." It's a drug where a meaningful number of people get real improvement in desire and are willing to tolerate the nausea, and a meaningful number of people find the side effects aren't worth a modest benefit and stop. Subgroup analyses from RECONNECT looked at which patient characteristics predicted better response, which is useful context for a prescriber trying to set expectations before you start, rather than after four doses of nausea ^[10]. This is exactly the kind of judgment call that benefits from being made with a prescriber who has seen the trial data and can talk through your specific cardiovascular history, other medications, and what "low desire" actually means for you, rather than guessing from a label. Bremelanotide Rx's provider-reviewed access path connects that conversation to a licensed prescriber and a pharmacy partner that fulfills the FDA-approved product, rather than an unverified source with no safety data behind it.

What should you actually track if you're using PT-141 regularly?

A few concrete things are worth logging, especially in the first few months. Blood pressure before and after doses, particularly if you have any cardiovascular risk factors, since that's the effect with the clearest mechanistic backing and the clearest FDA warning ^[4] . Nausea severity and timing relative to the dose, since a subset of patients see it ease with continued use and knowing your own pattern helps you and your prescriber decide if it's worth continuing ^[4]. Any new skin darkening, especially on the face or gums, since that's the pigmentation effect that may not fully reverse ^[4]. And simply whether you're seeing the effect you wanted on desire, since a drug with this side effect profile that isn't helping isn't worth continuing. For guidance on the injection itself, including site rotation to manage local reactions, see PT-141 injection sites and PT-141 how to inject. Understanding how long a single dose stays active in the body also helps make sense of why the effects (both wanted and unwanted) cluster within hours of dosing rather than lingering for days; see PT-141 half life.

Frequently asked questions

Does PT-141 cause permanent side effects?

Most reported side effects (nausea, flushing, headache) are transient and tied to each dose. The one exception flagged in FDA labeling is skin or gum hyperpigmentation, reported in a smaller subset of trial participants, which may not fully resolve after stopping the drug. There's no published evidence of other permanent effects, but no multi-year human data exists either ^[5].

How long do PT-141 side effects last after each dose?

Nausea and flushing are typically described as transient, occurring within hours of the subcutaneous injection and resolving the same day. Blood pressure increases are also described as transient per-dose effects rather than a sustained elevation ^[5][22]. Individual experience varies, and some people report nausea intense enough to warrant lying down until it passes.

Is PT-141 safe to use every month for years?

Nobody knows for certain. The longest published controlled data covers up to 52 weeks in an open-label extension of the phase 3 program ^[4]. No new safety signal emerged in that window, but there's no published data past roughly a year, so multi-year safety is genuinely unstudied territory rather than confirmed safe.

Can PT-141 cause high blood pressure long term?

It causes a transient blood pressure rise after each dose rather than a documented progressive, cumulative increase. The FDA specifically warns against use in people with uncontrolled hypertension or cardiovascular disease ^[5]. A clinical review on hypertension and female sexual dysfunction recommends monitoring, especially in people with existing cardiovascular risk ^[22].

Why does PT-141 cause nausea when Viagra doesn't?

PT-141 (bremelanotide) works centrally, activating melanocortin receptors in the brain, rather than acting locally on blood vessels like sildenafil (a PDE5 inhibitor) ^[6][19]. Melanocortin receptor activation broadly triggers nausea as a common downstream effect, which is why nausea, not a vascular symptom, is bremelanotide's signature side effect, reported in roughly 40% of users in some trial data ^[11].

Does PT-141 affect weight or metabolism long term?

The melanocortin system it acts on is also involved in appetite regulation, and it's studied separately in metabolic disorder research ^[6]. Two phase 1 trials specifically examined bremelanotide's effect on body weight in obese women ^[26], but it is not approved or established as an effective weight loss treatment, and no clear long-term weight effect is confirmed in the HSDD trial population.

Can PT-141 stop working after long term use (tolerance)?

The published trial data, out to about a year, doesn't report a clear pattern of diminishing efficacy with continued use. What's reported is that nausea intensity sometimes eases with repeat dosing ^[5]. There's no long-term data confirming or ruling out tolerance to the desire-related effect beyond that window.

Who should avoid long term PT-141 use entirely?

People with uncontrolled hypertension or cardiovascular disease need clearance from a prescriber first, given the drug's blood pressure effects ^[5][22]. It's approved only for premenopausal women with acquired, generalized HSDD, not for postmenopausal women, men, or arousal/orgasm disorders specifically. Anyone whose low desire stems from an untreated separate cause should address that first ^[2].

Is the skin darkening from PT-141 dangerous?

Hyperpigmentation reported with bremelanotide (typically focal darkening on skin, gums, or breasts) is a cosmetic effect tied to melanocortin receptor activation, not described as a dangerous or cancerous change in the trial data ^[5]. It's flagged because it may persist after stopping the drug, which makes it worth discussing with a prescriber before starting rather than a medical emergency if noticed.

How is PT-141 different from flibanserin (Addyi) for long term use?

Both treat HSDD, but flibanserin is a daily pill affecting serotonin pathways, while bremelanotide is an as-needed injection affecting melanocortin pathways. A regulatory commentary comparing the two raised similar concerns about modest average effect sizes relative to side effect burden for both drugs ^[16], though their side effect profiles differ (flibanserin carries a sedation and alcohol interaction warning distinct from bremelanotide's nausea profile).

Does bremelanotide have any studied anti-cancer or unusual research applications?

A 2024 laboratory study found that bremelanotide induced cell death in glioblastoma (brain tumor) cells in vitro by suppressing a protein called survivin ^[27]. This is early-stage cell culture research exploring a possible anti-tumor application, not a safety finding, and has no bearing on cancer risk for people using Vyleesi for HSDD.

What's the maximum safe dosing schedule for long term PT-141 use?

The FDA-approved label limits bremelanotide to one dose within 24 hours and no more than eight doses per month. This schedule is what the phase 3 and extension trial safety data is actually based on ^[1][4]. Exceeding it isn't studied, and there's no evidence it's safe to do so; see PT-141 dosage for the full approved schedule.

Sources

1. Obstetrics and Gynecology, 2019 (PMID 31599840): Two randomized phase 3 RECONNECT trials, each 24 weeks, supported FDA approval of bremelanotide for HSDD in premenopausal women
2. Journal of Midwifery & Women's Health, 2021 (PMID 34510696): HSDD diagnosis requires ruling out other causes of low desire (relationship, psychiatric, hormonal) before treatment
3. Bremelanotide: First Approval, Drugs, 2019 (PMID 31429064): Open-label extension of the phase 3 program followed participants for up to 52 weeks, the longest published safety window
4. Safety Profile of Bremelanotide Across the Clinical Development Program, Journal of Women's Health, 2022 (PMID 35147466): Nausea, flushing, headache, injection site reactions, transient blood pressure rise, and hyperpigmentation are the documented side effects across the full clinical program
5. Targeting the central melanocortin system for the treatment of metabolic disorders, Nature Reviews Endocrinology, 2023 (PMID 37365323): The melanocortin receptor system (including MC4R) is a target in metabolic and appetite regulation research
6. Ligands for Melanocortin Receptors, Biomolecules, 2022 (PMID 36291616): Melanocortin receptors have systemic reach beyond desire pathways, consistent with body-wide side effects like nausea and flushing
7. Bremelanotide: New Drug Approved for Treating HSDD, The Annals of Pharmacotherapy, 2020 (PMID 31893927): Injection site reactions are documented among bremelanotide's reported adverse events
8. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide, Journal of Sexual Medicine, 2019 (PMID 31277966): Nausea was reported in a substantial share of bremelanotide users (up to roughly 40% in some trial reporting), with flushing as the second most common effect
9. Bremelanotide and flibanserin for low sexual desire in women, Drug and Therapeutics Bulletin, 2021 (PMID 34642243): A regulatory commentary questioned whether approval standards for bremelanotide and flibanserin adequately weigh modest effect sizes against side effect burden
10. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies, Journal of Women's Health, 2022 (PMID 35230162): Subgroup analyses of RECONNECT examined which patient characteristics were associated with treatment response
11. The neurobiology of bremelanotide for HSDD in premenopausal women, CNS Spectrums, 2022 (PMID 33455598): Bremelanotide's effect on desire is understood to act centrally on brain dopaminergic pathways rather than on genital vascular tissue
12. Small Effects, Questionable Outcomes: Bremelanotide for HSDD, Journal of Sex Research, 2024 (PMID 36809187): A peer-reviewed critique argued the benefit-to-side-effect ratio in bremelanotide's main trials is questionable
13. Polymorphism of Melanocortin Receptor Genes, Diseases (Basel), 2025 (PMID 41002740): Melanocortin receptor gene variants are linked to inflammatory disease traits, reflecting broader receptor biology beyond desire pathways
14. Management of Hypertension with Female Sexual Dysfunction, Medicina (Kaunas), 2022 (PMID 35630054): Blood pressure monitoring is recommended for bremelanotide candidates with existing cardiovascular risk factors
15. Re-Analyzing Phase III Bremelanotide Trials for HSDD in Women, Journal of Sex Research, 2021 (PMID 33678061): An independent re-analysis of the phase 3 trial data questioned the clinical significance of the desire score improvements relative to reported side effects
16. Effect of bremelanotide on body weight of obese women, Diabetes, Obesity & Metabolism, 2022 (PMID 35170192): Two phase 1 randomized controlled trials specifically examined bremelanotide's effect on body weight in obese women
17. Melanocortin Receptor Agonist Bremelanotide Induces Cell Death in Glioblastoma Cells, Anticancer Research, 2024 (PMID 39197897): A 2024 laboratory study found bremelanotide induced cell death and growth inhibition in glioblastoma cells via suppression of survivin